NOTES TO CONSOLIDATED  FINANCIAL STATEMENTS LONG-TERM DEBT, CREDIT FACILITIES AND  LEASE OBLIGATIONS Note 8. Amortization expense related to other intangible assets  for the years ended December 31, 2002 and 2001 was  $9.5 million and $9.9 million, respectively. Estimated amortization expense for each of the years ending  December 31 is as follows (in millions): Note 7.  ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Included in debt at December 31, 2002 were unsecured notes denominated in various foreign currencies as follows (in millions):  Future minimum lease payments (including interest) under noncancelable operating leases and aggregate debt maturities at December 31, 2002 were as follows:  The weighted average interest rate under the Credit Facilities was 4.79% at December 31, 2002, including the effect of interest rate swap agreements. The rates have been calculated using rates in effect at December 31, 2002, some of which are floating rates that reset periodically.  Edwards Lifesciences utilizes interest rate swap agreements in managing its exposure to interest rate fluctuations. Interest rate swap agreements are executed as an integral part of specific debt transactions. Edwards Lifesciences’ interest rate swap agreements involve agreements to receive a floating rate and pay a fixed rate, at specified intervals, calculated on an agreed-upon notional amount. As of December 31, 2002, Edwards Lifesciences had in place four interest rate swaps with a total notional amount of $199.4 million to swap floating rate United States dollar and Yen denominated debt obtained under the Company’s revolving credit facilities for fixed rates. The original maturities of the interest rate swap agreements are between three and five years.  agreement. The Credit Facilities contain various financial and other covenants of Edwards Lifesciences, including a maximum leverage ratio and a minimum interest coverage ratio. All amounts outstanding under the $430.0 million credit agreement have been classified as long-term obligations, as these borrowings will continue to be refinanced pursuant to this credit agreement. 2003 $ 8.7 2004 8.7 2005 8.7 2006 8.5 2007 8.5 December 31, (in millions) 2002 2001 Accounts payable $ 69.5 $ 53.1 Employee compensation  and withholdings 38.4 33.5 Property, payroll and other taxes 33.7 31.5 Other accrued liabilities 56.3 65.4 $ 197.9 $ 183.5 Aggregate Operating Debt (in millions) Leases Maturities 2003 $ 5.8 $ — 2004 5.4 — 2005 3.3 245.5 2006 3.0 — 2007 1.0 — Thereafter — Total obligations and commitments $ 18.5 $ 245.5 Japanese Yen 13,700.0 Euro 15.0 Swiss Franc 5.0 Edwards Lifesciences entered into two unsecured revolving credit agreements (“the Credit Facilities”) as of the Distribution, providing for up to an aggregate of $530.0 million in borrowings in multiple currencies. Borrowings currently bear interest at the London interbank offering rate (LIBOR) plus 0.78%, which includes a facility fee. One of the credit agreements provides for long-term borrowings up to an aggregate of $430.0 million and expires on March 30, 2005. The other credit agreement provides for short-term borrowings up to an aggregate of $100.0 million and expires on March 27, 2003. The Company will replace the $100.0 million credit agreement with a similar credit agreement through  March 2004. As of December 31, 2002, approximately  $245.5 million was outstanding under the $430.0 million credit agreement. Edwards Lifesciences pays a facility fee, regardless of available or outstanding borrowings, currently at an annual rate of 0.15% for the $430 million credit agreement and 0.125% for the $100.0 million credit S65 Edwards Lifesciences Corporation